Dianthus Therapeutics, Inc. (DNTH) vs Erasca, Inc. (ERAS)

Dianthus Therapeutics, Inc. and Erasca, Inc. are both Biotechnology companies. Dianthus Therapeutics, Inc. and Erasca, Inc. are of similar size ($5.1B and $5.1B). Erasca, Inc. has the higher net margin (0.00% vs −10,097.0%) and the lower return on invested capital (−203.1% vs −47.7%). Across the 13 metrics below, Dianthus Therapeutics, Inc. leads on 8 and Erasca, Inc. on 5.

Valuation

Metric DNTH ERAS Biotechnology median
P/E n/m n/m 7.88
P/S 2,605.77 n/m 11.47
P/B 4.23 12.26 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2,140.00 n/m 10.73
Earnings yield (4.69%) (6.67%) (28.84%)
Free cash flow yield (3.14%) (5.68%) (23.03%)

Profitability

Metric DNTH ERAS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (11,441.39%) 0.00% 0.00%
Net margin (10,096.95%) 0.00% 0.00%
Free cash flow margin (8,177.99%) 0.00% 0.00%
Return on equity (26.07%) (78.25%) (57.72%)
Return on assets (24.98%) (65.25%) (49.22%)
Return on invested capital (47.74%) (203.13%) 0.00%

Growth

Metric DNTH ERAS Biotechnology median
Revenue growth (TTM) (60.77%) — 5.64%
EPS growth (last fiscal year) (64.71%) 36.23% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNTH ERAS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 26.10 8.29 4.73
Net debt to EBITDA 2.20 1.93 0.96

Dividend

Metric DNTH ERAS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DNTH ERAS Biotechnology median
Market cap 5.07b 5.08b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack